Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus SIRT vs Lenvatinib in TACE-Refractory HCC
NCT06904196Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Apr 2025; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06904196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904196.